Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population

摘要: AbstractObjective: Evaluate the clinical and economic consequences of fetal trisomy 21 (T21) screening with non-invasive prenatal testing (NIPT) in high-risk pregnant women.Methods: Using a decision-analytic model, we estimated number T21 cases detected, invasive procedures performed, corresponding euploid losses total costs for three strategies: first trimester combined (FTS), integrated (INT) or NIPT, whereby NIPT was performed patients (women 35 years older women positive conventional test). Modeling based on 4 million cohort US.Results: at base case price $795, more clinically effective less costly (dominant) over both FTS INT. detected 4823 5330 procedures. 3364 108 364 INT 3760 108 760 28% 43% compared to IN...